Phenylbutyramide, also known as 4-phenylbutyramide, is a chemical compound with the formula C10H13NO. It is a white solid that is soluble in water and ethanol. Phenylbutyramide is synthesized by the reaction of phenylacetic acid with butylamine. It has been shown to have a variety of pharmacological effects, including anticonvulsant, antidepressant, and analgesic effects. It is also being studied for its potential use in treating a number of diseases, including epilepsy, depression, and pain. Phenylbutyramide is of interest to researchers because it is a potent inhibitor of histone deacetylase (HDAC), an enzyme that plays a role in gene expression. HDAC inhibitors have been shown to have therapeutic potential in a variety of diseases, including cancer, neurodegenerative disorders, and inflammatory diseases. Phenylbutyramide is currently being investigated in clinical trials for its safety and efficacy in treating these diseases.'
| ID Source | ID |
|---|---|
| PubMed CID | 7011 |
| CHEMBL ID | 3039472 |
| CHEBI ID | 93832 |
| SCHEMBL ID | 232920 |
| MeSH ID | M0055903 |
| Synonym |
|---|
| BRD-A25537246-001-02-9 |
| lipilisol |
| nivonorm |
| geriapan |
| 2-phenylbutyramide |
| th 4128 |
| substerina |
| 90-26-6 |
| normosterolo |
| .alpha.-phenylbutyramide |
| phenetamide |
| redusterol |
| eusterol |
| geristerol |
| hyposterol |
| phenetamid |
| butyramide, 2-phenyl- |
| nsc1861 |
| benzeneacetamide, .alpha.-ethyl- |
| nsc-1861 |
| .alpha.-toluamide, .alpha.-ethyl- |
| wln: zvy2&r |
| phenexan |
| 2-phenylbutanamide |
| phenylethylacetamide |
| DIVK1C_006980 |
| alpha-phenylbutyramide |
| phenylbutyramide |
| benzeneacetamide, alpha-ethyl- |
| einecs 201-980-4 |
| butyramide, alpha-phenyl- |
| nsc 1861 |
| ai3-01390 |
| brn 3197469 |
| alpha-toluamide, alpha-ethyl- |
| SPECTRUM_001621 |
| SPECTRUM5_001398 |
| BSPBIO_002283 |
| NCGC00095335-01 |
| KBIOGR_001214 |
| KBIO2_004669 |
| KBIO1_001924 |
| KBIO2_002101 |
| KBIOSS_002101 |
| KBIO3_001503 |
| KBIO2_007237 |
| SPECTRUM2_000492 |
| SPECTRUM3_000652 |
| SPECPLUS_000884 |
| SPBIO_000383 |
| SPECTRUM4_000627 |
| SPECTRUM1504223 |
| NCGC00095335-02 |
| AC-11144 |
| A843480 |
| CCG-39566 |
| AKOS008977373 |
| j95wo7w7d4 , |
| unii-j95wo7w7d4 |
| 4-09-00-01818 (beilstein handbook reference) |
| FT-0622441 |
| fenbutyramide |
| CHEMBL3039472 |
| SCHEMBL232920 |
| W-100336 |
| .alpha.-phenylbutyramide [mi] |
| .alpha.-phenyl-.alpha.-ethylacetamide |
| primidone impurity c [ep impurity] |
| .alpha.-ethyl-.alpha.-phenylacetamide |
| mfcd00025511 |
| CHEBI:93832 |
| (2rs)-2-phenylbutanamide |
| alpha-phenyl-alpha-ethylacetamide |
| Q27165566 |
| benzeneacetamide,a-ethyl- |
| primidone impurity c |
| DTXSID60870423 |
| (+/-)-2-phenylbutyramide |
| BRD-A25537246-001-03-7 |
| D97844 |
| SB75764 |
| AS-81003 |
| Z68590268 |
| Class | Description |
|---|---|
| acetamides | Compounds with the general formula RNHC(=O)CH3. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE | Homo sapiens (human) | Potency | 0.1000 | 0.0032 | 45.4673 | 12,589.2998 | AID2517 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID977599 | Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM | 2013 | Molecular pharmacology, Jun, Volume: 83, Issue:6 | Structure-based identification of OATP1B1/3 inhibitors. |
| AID977602 | Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM | 2013 | Molecular pharmacology, Jun, Volume: 83, Issue:6 | Structure-based identification of OATP1B1/3 inhibitors. |
| AID1159550 | Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening | 2015 | Nature cell biology, Nov, Volume: 17, Issue:11 | 6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling. |
| AID1159607 | Screen for inhibitors of RMI FANCM (MM2) intereaction | 2016 | Journal of biomolecular screening, Jul, Volume: 21, Issue:6 | A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (20.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.53) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (20.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 4 (80.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||